[PDF] Top 20 Response predictors to treatment with pegylated interferon in chronic hepatitis B

... the response to the treatment of chronic hepatitis B has become progressively more important as a factor of therapeutic ...moment to initiate treatment, as well as ... See full document

... Guidelines to HCV treatment (2007) recommended that the irst choice treatment for patients with chronic hepatitis C (CHC) and genotype 2 or 3 is interferon alpha (IFN) ... See full document

... polymorphism in the vitamin D cascade, CYP27B1-1260 rs10877012, suggests a role of vitamin D in the response to treatment of chronic hepatitis ...C. In line ... See full document

... known to have developed SVR after therapy with dif- ferent forms of IFN monotherapy or IFN combined with RBV were eligible for the ...antiviral treatment, all patients had serum positivity for ... See full document

... patients with CHC, 120 did not meet the criteria for inclusion: 24 for being in treatment during the data collection period; 2 because they suspended treatment before completing it due ... See full document

... need to deal with “difficult” patients and in a “difficult” environment, such as a prison, such an approach allows a significantly-increased simplification and speeds up both diagnostic and ... See full document

... current treatment protocols, the rate at which an SVR is achieved ranges from 54% to 56% after the use of the combination of PEG-IFN-α (either formulation) and ribavirin, which is considerably higher than ... See full document

... presented to explain the relationship between elevated levels of CXCL10 and poor response ...receptors in circulating CTL (Larrubia et ...result in an accumulation of effector T cells ... See full document

... issue in the management of patients with chronic hepatitis C (CHC) owing to the difficulty of treatment with pegylated inter- feron/ribavirin ...treated with ... See full document

... previous treatment with IFN-α, viremia, presence of serum HBeAg, HBcAg in situ, and liver ...used to analyse the viral load median (represented by the log of the number of genomes/ml) ... See full document

... of hepatitis C virus (HCV) genotypes and their influence on response to long term recombinant-interferon-alpha (r-IFN-α) therapy in Brazilian ...and with histologically confirmed ... See full document

... Infection with hepatitis C virus is an important public health problem and one of the most frequent chronic infectious diseases worldwide, with a global prevalence of 1%-2% ...[1]. ... See full document

... patients with chronic hepatitis C according to diagnostic criteria (abnormal level of serum alanine aminotransferase, ALT, and positive anti-HCV and HCV-RNA in serum) were selected from ... See full document

... [18] to stabilize the variance of raw proportions (r/n), and then pooled the proportions by a DerSimonian–Laird random- effects model ...heterogeneity in pooled proportions, we calculated the I 2 value when ... See full document

... Recurrent hepatitis C after orthotopic liver transplantation (OLT) is universal and can lead to graft failure and, consequently, reduced ...survival. Hepatitis C treatment can be used ... See full document

... of treatment) are observed in around half of treated patients and many factors such as age, genotype, viral load and body weight are related with treatment outcome ...HCV treatment ... See full document

... a chronic disease in a large proportion of patients, ranging from 55% to 90%; it has a progressive fibrotic ...Up to 20% of the cases may culminate in cirrhosis; which may cause ... See full document

... related to the presence of cryoglobulin occurred in 24% of the positive subjects, resulting in a 6% overall prevalence of symptomatic cryoglobulin for all of the patients ...corroborate with ... See full document

... patients with chronic hepatitis C virus, with detectable HCV-RNA in the peripheral blood detected by PCR, who received a combined therapy of INF-α+RBV, which was provided by the Health ... See full document

... primary treatment discontinuation due to the absence of virological response at week 12 of treatment ...(23.3%), to adverse effects (15.2%) or to patients’ voluntary request for ... See full document